Tuesday, November 3rd at 11:00am EST / 5:00pm CET Genome Safety Webinar Series: Regulatory Expectations, Practical Workflows, ...
The ISSCR iPSC 20th Anniversary Symposium convenes the global stem cell community in Kyoto, the birthplace of iPSCs, to mark ...
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today ...
Six patients with glycogen storage disease type Ia have received a single infusion of BEAM-301, an in vivo base editor ...
Researchers in Australia have reprogrammed the RNA-cutting enzyme PspCas13b to destroy the fusion transcripts that drive many ...
There is currently no cure for Friedreich’s ataxia. However, CRISPR Medicine News spoke with Dr Céline Rocca about the importance of precision models and how she used CRISPR to develop a blood stem ...
Minutes ago, French and Italian researchers published a gene-editing strategy using adenine base editors to precisely repair two of the most common severe β-thalassaemia mutations, restoring adult ...
Six patients with glycogen storage disease type Ia have received a single infusion of BEAM-301, an in vivo base editor designed to correct the R83C... Researchers built a three-layer human ...
Life Edit Therapeutics was recently acquired and is now a subsidiary of ElevateBio. The company develops multiple novel gene-editing technologies, including CRISPR-Cas, base editing and ...
Preliminary Phase 1 data from Fate Therapeutics indicate that its off-the-shelf CAR T-cell therapy, FT819, can induce early clinical responses in patients with treatment-resistant systemic sclerosis ...
A new CRISPR-based strategy turns cancer cells' own mutant transcripts against them, opening a potential route to one of oncology's most stubborn unsolved problems: the targeting of mutant p53. Rather ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results